Holen Sie sich die Stockscreener-App
71.19
0.14%
0.10
Handel nachbörslich:
71.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$71.09
Offen:
$70.83
24-Stunden-Volumen:
2.96M
Relative Volume:
0.68
Marktkapitalisierung:
$41.85B
Einnahmen:
$5.72B
Nettoeinkommen (Verlust:
$4.17B
KGV:
10.21
EPS:
6.97
Netto-Cashflow:
$259.90M
1W Leistung:
+0.34%
1M Leistung:
-0.29%
6M Leistung:
+6.92%
1J Leistung:
-25.18%
1-Tages-Spanne:
$70.32
$71.56
1-Wochen-Bereich:
$69.82
$72.29
52-Wochen-Spanne:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
71.19 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
|
ABT
Abbott Laboratories
|
131.35 | 227.80B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.80 | 149.09B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.54 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.98 | 114.12B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - Marketscreener.com
Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - Marketscreener.com
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com India
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock - Investing.com India
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock - Investing.com India
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock By Investing.com - Investing.com UK
Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group - Insider Monkey
Director Heisz Stone Sells Shares of Edwards Lifesciences Corp - GuruFocus.com
Edwards Lifesciences Corp. to Host Earnings Call - ACCESS Newswire
Jefferies maintains hold on Edwards Lifesciences stock, target $71 - Investing.com
Q2 EPS Forecast for Edwards Lifesciences Cut by Analyst - Defense World
Blood Pressure Monitor Market Growth USD 4.36 Billion by 2035 at a 6.1% of CAGR | Future Market Insights, Inc. - GlobeNewswire Inc.
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight - GuruFocus.com
Sabal Trust CO Has $2.23 Million Stake in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Oppenheimer & Co. Inc. Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Truist Financial Corp Buys 6,676 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Impax Asset Management Group plc Increases Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences CFO Scott Ullem sells $796k in stock - Investing.com
National Pension Service Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
HealthInvest Partners AB Buys 31,791 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
BankPlus Trust Department Takes $844,000 Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Union Bancaire Privee UBP SA Makes New $1.12 Million Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Hardman Johnston Global Advisors LLC Sells 7,170 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Private Advisor Group LLC Acquires 9,440 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Bank of New York Mellon Corp Has $1.34 Billion Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Catheter Market Global Report and Company Analysis 2025-2033 Featuring Abbott Laboratories, BD and Co, Boston Scientific, Teleflex, Medtronic, Johnson & Johnson, Edwards Lifesciences, Stryker - Yahoo Finance
A Look Into Edwards Lifesciences Inc's Price Over Earnings - Benzinga
W.G. Shaheen & Associates DBA Whitney & Co Increases Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference - BioSpace
What Will Edwards Lifesciences Reveal at Next Week's Major Healthcare Conference? - StockTitan
Edwards Sees ‘Emerging’ Opportunities in Structural Heart Disease - Orange County Business Journal
FRIDAY INVESTOR DEADLINE: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitEW - ACCESS Newswire
CIBC Asset Management Inc Sells 31,973 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Principal Financial Group Inc. Sells 23,591 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Pittenger & Anderson Inc. Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Baillie Gifford & Co. Buys 498,100 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Has $287,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Chevy Chase Trust Holdings LLC - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
3.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):